Subcutaneous administration of proton pump inhibitors in palliative care patients: a review of clinical effectiveness and guidelines

Murphy G, Spry C
Record ID 32011001284
Authors' recommendations: There is evidence from three case reports published in one article describing the subcutaneous administration of omeprazole in palliative care patients. An injectable form of omeprazole is not, however, commercially available in Canada. No guidelines about the administration of PPIs in palliative care patients were identified. This lack of evidence perhaps should be considered when making a decision about the subcutaneous administration of PPIs in this patient population. Due to the lack of evidence, no conclusions can be drawn regarding the safety and efficacy of subcutaneous administration of PPIs.
Project Status: Completed
Year Published: 2009
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Palliative Care
  • Proton Pump Inhibitors
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.